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The bulk of tumor is thought to be composed of differenti-ated cancer cells, with only a small fraction consisting of 
pluripotent self-renewing putative cancer stem cells (CSCs) 
(1). Recurrence or progression of tumor after treatment is often 
caused by growth and differentiation of the CSCs, enabled 
by increased signaling of Hedgehog (1) and Notch in CSCs 
(2). Preclinical studies report that CSCs are more resistant to 
systemic radiotherapy than differentiated cancer cells that are 
often observed in the bulk of tumor mass (2). Therefore, cura-
tive therapy for advanced/metastatic lung cancer may require 
doubling down, a two-pronged approach: cytotoxic or appropri-
ate molecular-targeted therapy to debulk the majority of tumor 
cells in combination with Notch and/or Hedgehog signaling 
inhibitors to eliminate the CSCs to prevent tumor growth/recur-
rence (1). In our quest to improve outcomes for patients with 
advanced malignancies, targeting the Notch signaling pathway 
(NSP) and Hedgehog signaling pathway (HHSP) may lead to 
knocking out CSCs. Targeting these pathways is an attractive 
means to inhibit CSC growth and differentiation. 
SUMMARY OF RESEARCH PRESENTATIONS
An overview of putative CSCs, NSP, and HHSP was pro-
vided by Dr. Carbone. An important regulator of development 
and cell fate in various tissues, the NSP has four highly con-
served transmembrane receptors (Notch1–4) (3). The Notch 
receptor undergoes a two-stage cleavage by tumor necrosis 
factor-α-converting enzyme and γ-secretase when bound by 
an appropriate ligand (3). All agents in clinical trials that tar-
get the NSP are inhibitors of γ-secretase. 
An important regulator of tissue polarity, patterning, 
and stem cells maintenance in various tissues, the HHSP 
has two Patched (PTCH) transmembrane receptors (PTCH1 
and PTCH2) (1, 3). When the appropriate ligand binds to the 
PTCH receptor, Smoothened (SMO) is derepressed and a cas-
cade of events ultimately leads to Glioma-associated onco-
gene homologue (GLI) transcription activation (1). All agents 
in clinical trials that target the HHSP are inhibitors of SMO. 
To date, clinical results on at least three drugs that target NSP 
and five drugs that target the HHSP have now been formally 
presented at national meetings. A few of these agents were 
highlighted at this meeting. 
NSP Targeting with γ-Secretase Inhibitors
Dr. Stewart provided some additional background on 
Notch, stating that it is commonly expressed in non–small-cell 
lung cancer (NSCLC), its expression is increased by hypoxia, 
and CSCs, defined by aldehyde dehydrogenase and CD133 
positive staining, have increased Notch signaling activity. In 
preclinical NSCLC studies, γ-secretase inhibitors increased 
poly adenosine diphosphate ribose polymerase cleavage and 
apoptosis and decreased cell line and tumor xenograft growth. 
In the phase I study with the γ-secretase inhibitor, RO4929097, 
a patient with colorectal cancer had a partial response, a patient 
with an epithelial sarcoma had a mixed response, and two 
patients with melanoma had minor responses. In NSCLC, this 
agent is being evaluated in a maintenance study for nonpro-
gressing advanced patients after first-line therapy. A phase I/
II study is evaluating this drug in combination with erlotinib in 
advanced-stage NSCLC. 
Dr. Wang presented the γ-secretase inhibitor, PF-03084014, 
currently in a phase I trial in solid tumors. This agent is dosed 
orally twice a day for 21 of 28 days; one patient with papillary 
thyroid cancer had a complete response and two patients with 
desmoid tumor had a partial response. At the last formal presen-
tation of this study, eight patients were still on study, with three 
individuals receiving drug for longer than 1 year. 
SMO Antagonists: The First HHSP Inhibitors  
in the Clinic
Dr. Melemed presented the SMO antagonist, 
LY2940680, currently in a phase I trial in solid tumors. The 
maximum tolerated dose of 400 mg has been identified. 
Toxicities were common class side effects including dysgeu-
sia, fatigue, alopecia, as well as, nausea and vomiting. Plans 
are in the works for a phase Ib/II trial combination with car-
boplatin/etoposide in patients with extensive-stage small-cell 
lung cancer (SCLC).
I presented the preclinical and clinical development of 
vismodegib (formerly known as GDC-0449), a synthetic SMO 
antagonist that has completed phase I/II studies. In two long-
term–treated patients with basal cell carcinoma (BCC) treated 
with vismodegib, no major safety signals were reported with 
dosing out to nearly 3 years (4). This agent demonstrated clini-
cal activity as a single agent in locally advanced and metastatic 
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BCC (5) and was approved by the Food and Drug Administration 
for use in this tumor type on January 30, 2012 (http://www.can-
cer.gov/cancertopics/druginfo/fda-vismodegib). Vismodegib is 
being evaluated in a number of clinical trials in combination 
with chemotherapy and/or targeted therapy. One of these is the 
E1508 trial that randomizes extensive-stage SCLC patients to 
cisplatin plus etoposide or an experimental arm, one of which 
consists of cisplatin plus etoposide plus vismodegib (www.
clinicaltrials.gov). 
FUTURE DIRECTIONS
At the 12th Annual Targeted Therapies of the 
Treatment of Lung Cancer meeting, several investigators 
presented data on recent developments surrounding agents 
that target NSP and HHSP. It is still too early to determine 
whether the strategies of targeting NSP via γ-secretase inhi-
bition will lead to statistically significant and meaningful 
gains that justify drug approval in NSCLC. The initial bar-
rier for demonstration of efficacy has been overcome for at 
least one SMO antagonist, vismodegib, in advanced BCC. 
There are a variety of phase II trials ongoing with a number 
of SMO antagonists, including the E1508 trial that com-
bines an SMO antagonist with cytotoxic chemotherapy in 
first-line therapy for extensive-stage SCLC. If the results 
of this particular study are statistically significant in favor 
of the experimental arm with an acceptable toxicity profile, 
then we may see an approval strategy for SCLC that would, 
hopefully, improve the armamentarium for this disease. For 
solid tumors such as NSCLC and SCLC, the strategy for 
maximum efficacy will likely involve targeting CSCs by 
doubling down inhibition of NSP and/or HHSP combined 
with tumor mass debulking via delivery of systemic cyto-
toxic or specific targeted therapies. 
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